Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of TQB2450 in Advanced Malignancy
NCT03460457Phase 1Unknown
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Mar 2018
- Primary completion
- Mar 2019
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, open-label, single-arm trial of benmelstobart in advanced malignant solid tumor, sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoints: Maximum Tolerated Dose at 21 days and Dose-Limiting Toxicity at 21 days. Status: unknown.
02
Drugs
benmelstobart
03
Conditions
advanced malignant solid tumor
Beyond the preview
Go deeper on NCT03460457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03460457.